XNK Therapeutics AB ('XNK'), a clinical stage, immunotherapy company focusing on cancer treatment by developing novel NK cell-based therapies, announced on Thursday that it has named Dr Anna-Karin Maltais as its new chief scientific officer, effective 17 October.
Dr Maltais is to serve as a member of the company's management team.
In the new role, Dr Maltais will oversee development and implementation of the company's scientific strategy.
Dr Maltais has previously led R&D activities and strategies within several organizations. Most recently Dr Maltais has served as Head of CMC, Biotech Research and Product Development, Global Rare Diseases at Chiesi Farmaceutici SpA.
enGene names new chief financial officer and head of Business Development
The American Board of Medical Specialties names new members of the board of directors
MedGenome names new Advisory Board chairman
MentalHealth.com names new Dr Jesse Hanson as new clinical director
Element Biosciences names new director
BD names new executive vice president and chief medical officer
Fuse Oncology names new chief technology officer
Halia Therapeutics names new vice president Regulatory Affairs and new senior medical director
Rivus Pharmaceuticals names new chief medical officer
K36 Therapeutics names new chief medical officer
Kyverna Therapeutics' fifth KYV-101 Investigational New Drug application receives US FDA approval
Nereid Therapeutics names new president and chief executive officer